Bloodless end to Boston Biomedica's failed placement:
This article was originally published in Clinica
Executive Summary
Boston Biomedica has managed to exit with some grace and apparently unharmed from its failed stock warrants placement programme with the Paradigm Group and National Securities Corp. Almost two year ago, Boston Biomedica placed an aggregate of 500,000 warrants with the two buyers, but over the course of the registration process, the share price dropped below the option price. The issue last week came to a bloodless close with all parties agreeing to a settlement agreement and mutual release, thereby rescinding or cancelling all obligations to pay exercise prices. Paradigm has also dropped legal proceedings against West Bridgewater, Massachusetts-based Boston Biomedica.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.